<DOC>
	<DOCNO>NCT01099631</DOCNO>
	<brief_summary>The work hypothesis oral administration attenuate strain Salmonella typhimurium safe efficacious patient unresectable hepatic metastasis solid tumor cancer . The primary objective study determine MTD Samonella typhimurium treatment .</brief_summary>
	<brief_title>IL-2 Expressing , Attenuated Salmonella Typhimurium Unresectable Hepatic Spread</brief_title>
	<detailed_description>This phase I study do evaluate dose escalation scheme oral administration attenuate strain Salmonella typhimurium express human interleukin-2 ( IL-2 ) patient unresectable hepatic metastasis solid tumor cancer . Standard Phase I dose escalation scheme use determine MTD Samonella typhimurium . Six dose level Salmonella study minimum 3 patient enrol dose level .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Histologic documentation malignancy ( solid tumor type ) spread liver deem unresectable , effective standard therapy available . Patients additional disease outside liver allow . Patients may receive number prior therapy ; however least 3 week must pass since last dose chemotherapy radiotherapy ( 6 week Nitrosoureas Mitomycin C ) prior study entry . Must recover acute toxicity ( define per National Cancer Institute 's Common Toxicity Criteria Adverse Events 3.0 ≤ grade 1 ) associate previous treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . Life expectancy great 2 month determine enrol investigator Adequate organ function within 1 week treatment start define : Adequate bone marrow reserve : leukocytes ≥ 3,000/μl , absolute neutrophil count ( ANC ) ≥ 1,500/μl , platelet ≥ 100,000/μl Hepatic : bilirubin ≤1.5 time institutional upper limit normal ( ×ULN ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 x ULN Renal : serum creatinine ≤ 1.5 x ULN Women childbearing potential sexually active men must agree use adequate contraception prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . Unable take oral drug clinically significant gastrointestinal abnormality may affect absorption investigational product include , limited : malabsorption syndrome , major resection stomach small bowel Receiving investigational agent Known central nervous system metastases Residing household close contact pregnant woman , young child ( age 1 year ) immune compromise person Engaged activity might pose risk widespread dissemination organism , include , limited ; health care , child care , food service . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation . Pregnant breastfeeding . Women child bear potential must negative serum urine pregnancy test within 7 day prior start treatment . Pregnancy test require postmenopausal surgically sterilize woman . Breastfeeding mother ask discontinue feeding infant prior enrol study . Known HIV infection , need chronic steroid immunosuppressant drug , medical condition investigator 's opinion result significant degree immunosuppression . Patients without identify HIV risk factor require HIV test eligible . Known active hepatitis B C infection Known HLA B27 Have permanent artificial implant ( , limit prosthetic valve joint . ) Any condition investigator 's opinion render patient high risk overwhelm infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Salmonella typhimurium</keyword>
	<keyword>unresectable hepatic cancer</keyword>
	<keyword>attenuate Salmonella typhimurium</keyword>
	<keyword>IL-2</keyword>
</DOC>